$ZBIO News

Zenas BioPharma Submits An FDA Biologics License Application For Obexelimab In Immunoglobulin G4-Related Disease

Zenas BioPharma Announces That Safety And Efficacy Outcomes From The Phase 3 INDIGO Trial Will Be Presented At The European Alliance Of Associations For Rheumatology Congress, June 3-6

HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $22

Zenas BioPharma Does First Patient In Its Phase 1 Trial Of ZB021, A Novel Oral IL-17AA/AF Inhibitor

Zenas BioPharma Q1 EPS $(1.46) Misses $(1.17) Estimate

Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026

Zenas BioPharma's Key Milestones And Market Context: Holding Through The BLA

Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk

Sector Update: Health Care Stocks Retreat Friday Afternoon

Zenas BioPharma shares are trading lower after it announced it priced concurrent public offerings of $200 million of convertible senior notes and 5 million shares at $20 per share.

Zenas BioPharma shares are trading lower after it announced it priced concurrent public offerings of $200 million of convertible senior notes and 5 million shares at $20 per share.

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Zenas BioPharma Prices $300M Concurrent Offerings Of $200M 2.50% Convertible Senior Notes Due 2032 And 5M Shares At $20 To Fund Obexelimab Launch

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Zenas BioPharma shares are trading lower after the company announced it commenced an underwritten public offering of convertible senior notes and shares of its common stock.

Zenas BioPharma Announces Proposed Concurrent Public Offerings Of Convertible Senior Notes And Common Stock; Amounts Not Disclosed

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch

Citigroup Maintains Buy on Zenas BioPharma, Lowers Price Target to $41

Guggenheim Maintains Buy on Zenas BioPharma, Raises Price Target to $55